Regeneron and Sanofi dosed the first patient outside of the United States with the rheumatoid arthritis drug Kevzara as part of a second global clinical trial assessing the medication as a treatment for COVID-19, the disease caused by the novel coronavirus pandemic.
Sanofi and Regeneron Pharmaceuticals expanded a clinical trial of the companies’ rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.
Spain’s Grifols said the latest results from a clinical trial of the company’s Alzheimer’s treatment show positive effects by achieving a reduction of the disease’s progression in patients with mild and moderate conditions.
The digital HCP engagement provider Physicians Interactive announced two major strategic moves in the past two months, acquiring the HCP content platform Univadis from Merck in October and then rebranding […]
